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Abstract
Background:  Tocopherols may protect against prostate cancer and cardiovascular disease
(CVD).
Methods: We assessed the effect of walnuts, which are rich in tocopherols, on markers of
prostate and vascular health in men at risk for prostate cancer. We conducted an 8-week walnut
supplement study to examine effects of walnuts on serum tocopherols and prostate specific antigen
(PSA). Subjects (n = 21) consumed (in random order) their usual diet +/- a walnut supplement (75
g/d) that was isocalorically incorporated in their habitual diets. Prior to the supplement study, 5
fasted subjects participated in an acute timecourse experiment and had blood taken at baseline and
1, 2, 4, and 8 h after consuming walnuts (75 g).
Results: During the timecourse experiment, triglycerides peaked at 4 h, and gamma-tocopherol
(γ-T) increased from 4 to 8 h. Triglyceride – normalized γ-T was two-fold higher (P = 0.01) after 8
versus 4 h. In the supplement study, change from baseline was +0.83 ± 0.52 µmol/L for γ-T, -2.65
± 1.30 µmol/L for alpha-tocopherol (α-T) and -3.49 ± 1.99 for the tocopherol ratio (α-T: γ-T). A
linear mixed model showed that, although PSA did not change, the ratio of free PSA:total PSA
increased and approached significance (P = 0.07). The α-T: γ-T ratio decreased significantly (P =
0.01), partly reflecting an increase in serum γ-T, which approached significance (P = 0.08).
Conclusion: The significant decrease in the α-T: γ-T ratio with an increase in serum γ-T and a
trend towards an increase in the ratio of free PSA:total PSA following the 8-week supplement study
suggest that walnuts may improve biomarkers of prostate and vascular status.
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Introduction
Cancer is a major cause of mortality worldwide. In the
United States, it is second only to heart disease [1]. Pros-
tate cancer is the most common type of cancer among
men, with an incidence rate of one in six men [2]. Further-
more, because androgens may play a role in the smooth
muscle proliferation associated with the development of
both prostate cancer and CVD, men at increased risk for
prostate cancer also may be at increased risk for heart dis-
ease [3]. As many as one in four men over 60 years old
have symptoms of both prostate enlargement and high
blood pressure [3] and therefore have an increased risk for
both diseases [4]. Moreover, although a PSA concentra-
tion of 4.0 ng/mL (4.0 µg/L) or greater is often used in
screening for prostate cancer, more than 20% of men with
diagnosed prostate cancer have PSA levels below this cut-
point [5]. Thus, recent work has focused on using percent
free PSA (PFP) in combination with total PSA to improve
specificity of diagnosis and decrease false-positives [5].
Since prostate cancer and heart disease affect many men,
there is a need for affordable and practical preventive
options that target both diseases.
Epidemiologic studies suggest that the antioxidant vita-
min E, particularly the γ-T form, may hold promise in
decreasing risk of prostate cancer [6-8] and CVD [9-11]. In
cell culture studies, both α-T and γ-T inhibit proliferation
of vascular smooth muscle cells [12,13], an important
event in atherogenesis [12]. Furthermore, both α-T and γ-
T inhibit growth of malignant cells, including prostate
tumor cells [14-16], and a recent supplementation study
reported that the combination of α-T and γ-T significantly
increased nitric oxide release and was more potent in pre-
venting platelet aggregation than was α-T alone [17,18].
Walnuts may provide an inexpensive and practical
method for supplementing intake of both tocopherols
and other nutrients that may protect against prostate can-
cer. For example, 75 g of walnuts contain 0.52 mg α-T and
15.6 mg γ-T [19]. Walnuts also contain ellagic acid (590
µg/g) [20], which has been shown to effectively induce
apoptosis and inhibit angiogenesis [21,22]. In addition,
walnuts are a rich source of unsaturated fatty acids that
favorably affect CVD risk [23], and several recent feeding
studies with walnuts have reported a total and LDL cho-
lesterol lowering effect following consumption of about
70–80 g/d of walnuts [24-26].
The primary goal of the supplementation study was to
evaluate the effects of consuming 75 g/d of walnuts on
metabolic factors related to prostate cancer and CVD in
men at risk for these diseases. Furthermore, in order to
develop interventions using dietary γ-T as a preventive
strategy in prostate cancer and CVD, it is important to
understand its bioavailability. Previous work has shown a
significant increase in plasma γ-T following a fat-rich meal
supplemented with 0.4–0.8 mg γ-T per kilogram of body
weight [27], and walnuts contain polyunsaturated fatty
acids, which may protect against CVD [23] and may
enhance tocopherol absorption [28]. Our results indicate
that γ-T in walnuts is absorbed, demonstrating bioavaila-
bility from walnuts, which provided the requisite assur-
ance needed to conduct a longer term study to evaluate
the effects of γ-T on prostate and vascular health.
Methods
Subjects
Participants were healthy, non-smoking men between 45
and 75 years of age who resided in central Pennsylvania.
Participants had total PSA ≥ 2.0 ng/mL (2.0 µg/L), but
they did not have clinically diagnosed prostate cancer.
Newspaper ads and fliers were used for recruitment, and
potential subjects were screened by telephone. Exclusion
criteria included allergies to nuts and use of prescription
and non-prescription preparations known to alter PSA
(e.g. Saw Palmetto, Finesteride), hormone levels, blood
pressure or blood lipids. Men taking vitamin E supple-
ments were eligible if they discontinued use two months
before entering the study. Those who were eligible were
invited to a screening visit during which blood pressure
and PSA level were measured. Written informed consent
was obtained from each participant, and the Human Sub-
jects Committee at the Pennsylvania State University
approved the study.
Acute timecourse experiment
Study design
To verify that γ-T in the walnuts was absorbed, we con-
ducted an acute timecourse experiment prior to the feed-
ing study at the General Clinical Research Center (GCRC)
in University Park, PA. Participants (n = 5) were part of a
controlled feeding study in which walnuts accounted for
24% of total daily calories and had been following their
diet for 3 weeks to allow them to acclimate to the diet and
ensure stable baseline measures [29].
Following an overnight fast and a baseline blood collec-
tion, they consumed 75 g of walnuts. Postprandial
changes in serum concentrations of triglycerides, choles-
terol and tocopherols were assessed at 1, 2, 4 and 8 hours
after the walnuts were consumed, similar to acute time-
course experiments with serum lipids, which typically
measure concentrations over an 8-hour period [30-32].
Biochemical analyses
The Pediatric Research Laboratory at East Tennessee State
University analyzed serum triglycerides, total cholesterol
and tocopherols. The tocopherols were extracted with eth-
anol:hexane and analyzed using a modification of the
HPLC method described by Bieri [33]. An aliquot ofNutrition Journal 2008, 7:13 http://www.nutritionj.com/content/7/1/13
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plasma incubation mixture was mixed with ethanol con-
taining tocol as an internal standard and immediately
extracted into hexane containing BHT (227 µmol/L). The
hexane layer was removed and evaporated under a gentle
stream of nitrogen gas. The residue was dissolved in etha-
nol containing propyl gallate (236 mol/L) as an antioxi-
dant and injected into a reverse phase Altex-Ultrasphere-
ODS (Beckman Instruments, Inc., Fullerton, CA) 4.6 mm
ID × 25 cm column. The mobile phase was metha-
nol:water (99.5%:0.5%, vol:vol). A McPherson Model FL-
750 fluorescence detector (McPherson Instruments,
Acton, MA) was utilized with 294 nm excitation and 324
nm emission.
Enzyme kits from STANBIO (Boerne, TX) were used to
assay total cholesterol and triglycerides. Intra-assay coeffi-
cients of variation were 2.5% for total cholesterol and 3%
for triglycerides. Batches of subject samples were assayed
with each subject's samples grouped together in random
order.
Statistical methods
All statistical analyses were performed in SAS, version 8.0
(SAS Institute, Cary, NC), and differences were considered
significant at P < 0.05. All values are least-squares means
± SEM. Statistical analyses were performed using a linear
mixed model with time as the repeated factor.
Walnut supplement study
Study design
The study was designed as a two-period cross-over in
which participants received two treatments in random
order. Participants (n  = 21) spent the first eight-week
period on either a walnut supplement diet, in which they
consumed 75 g of walnuts per day (approximately 24% of
energy intake from walnuts, based on a diet with 2000
kcal.day), or their usual diet ("Average American Diet");
then, following a two-week break, they switched to the
other diet for eight-weeks. Participants kept five, three-day
food records, one set at baseline and additional records at
weeks 4 and 8 of each diet period. Clinic visits took place
at the GCRCs located in University Park, PA and Hershey,
PA (at the Milton Hershey Medical Center). Endpoint
clinic visits included blood pressure, weight measurement
and fasting blood collection (0.05 L). Participants were
instructed to maintain their baseline weight and activity
level throughout the study. To ensure that weight
remained constant during the walnut supplement diet,
subjects were instructed on strategies for isocalorically
substituting walnuts for other energy sources in the diet.
Participants were weighed while wearing indoor clothing
but without shoes on digital scales at weeks 1, 2, 3, 4, 6
and 8. During weeks 4 and 8 of both diet periods, partici-
pants met with a registered dietitian, who reviewed the
food records with participants to reinforce compliance
and suggest individualized strategies for weight mainte-
nance.
Diet
During the walnut supplement diet, participants received
75 g of walnuts per day. The walnuts were shelled and
unroasted English walnuts purchased from a single lot,
pre-weighed and packaged in 75 g amounts and stored
frozen at -17°C. Participants were instructed to replace
another fat source in their usual diet with the walnuts and
to consume the walnuts throughout the day with snacks
and meals to maximize tocopherol absorption [28,34].
Food record data were analyzed for intakes of energy, fat,
tocopherols and other nutrients using Nutrition Data Sys-
tem for Research software, version 5.0_35, 2004 (Nutri-
tion Coordinating Center, University of Minnesota,
Minneapolis, MN.)
Urinary symptoms
At endpoint clinic visits, participants completed a nine-
item American Urological Association questionnaire
measuring urinary symptoms [35]. The first seven ques-
tions asked participants to indicate, from 0 (not at all or
none) to 5 (almost always or ≥ 5 times per night), their
frequency of specific urinary symptoms, such as a need to
urinate within two hours of finishing urination or diffi-
culty postponing or beginning urination, in the last
month. Participants then totaled these scores to obtain a
"symptom score." The questionnaire was scored as fol-
lows: a "total symptom score" of 1–7 indicated that uri-
nary symptoms were mild (1 being the mildest); 8–19
indicated that symptoms were moderate, and a score of
20–35 indicated that symptoms were severe (35 being the
most severe).
Biochemical Endpoints
The sample analysis focused on serum biomarkers and
hormones that have been consistently associated with
prostate disease and CVD in past studies. The analyses
measured total, free and percent free PSA, testosterone
(total, bioavailable and percent bioavailable), 3α-andros-
tanediol glucuronide (a metabolite of dihyrotestoster-
one), estradiol, IGF-1, total cholesterol and lipids,
oxidized LDL and α- and γ-T. At endpoint clinic visits,
twelve-hour fasting blood samples were collected into
Vacutainer tubes (for the tocopherol analysis, samples
were drawn into Vacutainer tubes containing EDTA). Fol-
lowing collection, samples were centrifuged at 2600 × g
for 15 min. Plasma for the tocopherol analyses was treated
with propyl gallate, an antioxidant preservative, and all
samples were frozen at -70°C until analysis at the end of
the study.Nutrition Journal 2008, 7:13 http://www.nutritionj.com/content/7/1/13
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The GCRC Core Laboratory at Hershey Medical Center
conducted the assays for serum hormones, IGF-1 and PSA
levels, and the Pediatric Research Laboratory at East Ten-
nessee State University analyzed the triglycerides, total
cholesterol and tocopherols as described above for the
acute timecourse experiment. Total and free PSA levels
were determined using microparticle enzyme immu-
noassay on an automated immunoassay platform (Abbott
AxSYM, Abbott Laboratories, Chicago, Illinois). Total tes-
tosterone and estradiol were measured using solid-phase
radioimmunoassays. 3α-androstanediol glucuronide was
determined using a competitive, double antibody radio-
immunoassy with rabbit anti-androstanediol glucuro-
nide. IGF-1 was determined by chemiluminescence using
the Nichols Advantage automated system (Nichols Insti-
tute Diagnostics, Inc., San Juan Capistrano, CA). Free and
weakly-bound testosterone were measured using ammo-
nium sulfate precipitation of sex-hormone binding glob-
ulin-bound testosterone following equilibration of 3H-
testosterone with the binding proteins in the serum sam-
ple. Percent free testosterone was determined by scintilla-
tion counting of the supernatants.
Enzyme kits from STANBIO (Boerne, TX) were used to
assay HDL cholesterol, and the intra-assay coefficient of
variation was 2.2%. LDL cholesterol was calculated using
the Friedewald equation [36], and oxidized LDL was
measured using an enzyme kit from Alpco Diagnostics
(Windham, NH) with an intra-assay coefficient of varia-
tion of 3.6%. The laboratories analyzed batched samples
of blood with each subject's samples grouped together in
random order.
Blood Pressure Measurement
Blood pressure was measured by registered nurses using a
sphygmomanometer. Measurements were taken from the
right arm and were made after a 5-minute rest in the sit-
ting position with both feet flat on the floor. Two meas-
urements were made at each visit and averaged.
Statistical methods
All outcome variables were tested for sequence and period
effects using a linear mixed model; none were found, and
these factors were dropped from the final models. A
paired sample t-test (two-sided) was used to compare par-
ticipants' responses to the urinary symptoms question-
naire's "total symptom" score and to compare blood
pressure and dietary intake of energy, total fat and vitamin
E between the two diets. To measure change in lipids, PSA,
vitamin E and hormones, a difference score (∆) between
serum concentrations of each variable at baseline and
each diet period was calculated. For example, for each var-
iable, ∆a = concentration following usual diet – concentra-
tion at baseline and ∆w  = concentration following
intervention diet – concentration at baseline. Because
body weight change differed between the two diets (see
below), we tested whether covarying for change in weight
(vs. screening) significantly impacted diet-related change
in each of the outcome variables. Based on these analyses,
change in weight was included in the analyses of tocophe-
rols and IGF-1. In addition, fasting TG and PFP concentra-
tions were not normally distributed, so log-transformed
(base 10) concentrations were used in the mixed model
analyses and the resultant change scores and means
reported as geometric means. Values are reported as least-
squares means ± SEM unless otherwise noted.
Results
Acute timecourse experiment
Following consumption of 75 g of walnuts, the average
concentration of serum triglycerides rose from 0.87 ± 0.19
mmol/L at 1 h to a peak of 2.05 ± 0.19 mmol/L at 4 h. The
average concentration of serum total cholesterol was 5.95
± 0.43 mmol/L at 1 h and peaked at 6.21 ± 0.43 mmol/L
2 h after walnut consumption (Figure 1). Average serum γ-
T reached peak concentration of 4.41 ± 0.55 µmol/L
between 4 and 8 h (Figure 1). Average serum α-T reached
peak concentration of 32.4 ± 1.63 µmol/L between 2 and
4 h (Figure 1). Compared to baseline, serum triglycerides
were significantly elevated at 2 and 4 h (mean concentra-
tions of 1.29 ± 0.19 mmol/L, P = 0.05 at 2 h and 2.05 ±
0.19 mmol/L, P < 0.0001 at 4 h) (Figure 1). In the final
model, changes in total cholesterol and tocopherols were
not significant over time (P = 0.98 for cholesterol, P = 0.98
for α-T and P = 0.49 for γ-T), and changes in tocopherol
were not significant when adjusted for cholesterol. How-
ever, we observed a significant, two-fold increase (P  =
0.01) in the ratio of γ-T to serum triglycerides at 4 h com-
pared to 8 h.
Walnut supplement study
Subject characteristics
Twenty-two white males from central Pennsylvania vol-
unteered to participate in the walnut supplement study;
one participant with a prior history of gastrointestinal dis-
tress withdrew following a reoccurrence of symptoms dur-
ing the walnut diet. The average age was 65.9 years (range
was 55 to 75 years). Mean weight was 84.8 ± 2.9 kg at the
screening visit, 83.4 ± 2.8 kg at the end of the usual diet
and 84.3 ± 2.9 kg at the end of the walnut supplement
diet. Mean body mass index was 27.5 ± 3.5 during the
usual diet and 27.8 ± 3.7 during the walnut diet. Subjects
on the usual diet lost 1.36 ± 0.39 kg (P = 0.001), and sub-
jects on the walnut supplement diet maintained their
weight. Importantly, there was no weight gain during the
walnut supplement diet period.
Dietary intake
Aside from the nutrients provided by the walnuts, the par-
ticipants' diets were similar in energy, total fat and α-TNutrition Journal 2008, 7:13 http://www.nutritionj.com/content/7/1/13
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Effect of a 75 g walnut bolus on average serum concentrations of triglycerides (A), cholesterol (B), α-tocopherol (a-T) (C) and  γ-tocopherol (g-T) (D) over 8 h timecourse following consumption (time 0) Figure 1
Effect of a 75 g walnut bolus on average serum concentrations of triglycerides (A), cholesterol (B), α-tocopherol (a-T) (C) and 
γ-tocopherol (g-T) (D) over 8 h timecourse following consumption (time 0). Values are least-squares means ± SEM, n = 5. 
Asterisks indicate *P equal to or less than 0.05.Nutrition Journal 2008, 7:13 http://www.nutritionj.com/content/7/1/13
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during both diet periods (Table 1). The 75 g of walnuts
consumed each day during the walnut supplement diet
contained 490 kcal of energy, 48.9 g of fat, 0.52 mg of α-
T and 15.6 mg of γ-T [19], and a nutrient analysis of a sam-
ple of the walnuts used in our study showed that they con-
tained about 23 mg of γ-T and trace amounts of α-T (data
not shown), as expected. Analysis of the participants' diet
records during the walnut supplement diet period showed
significant increases (values are means ± SD) in energy
(478 ± 616 kcal/d; P = 0.003), total fat (44.4 ± 30.9 g/d; P
< 0.0001), monounsaturated fat (6.9 ± 13.3 g/d; P = 0.02),
polyunsaturated fat (29.1 ± 18.3; P  < 0.0001) and γ-T
(13.7 ± 7.99 mg/d; P < 0.0001), all of which were consist-
ent with the amount of each of these nutrients present in
75 g of walnuts (Table 1), suggesting that participants
were compliant with the walnut treatment.
Serum biomarkers and blood pressure
After controlling for weight, no significant differences
were detected in serum α-T, although the change in serum
γ-T approached significance (Table 2). However, after the
walnut supplement diet, the ratio of serum α-T:γ-T
decreased significantly (∆a = -0.51 ± 1.99, ∆w = -3.49 ±
1.99 µmol/L; P = 0.01) (Table 2). There were no signifi-
cant treatment effects on serum concentrations of triglyc-
erides, total cholesterol, LDL cholesterol, bioavailable
testosterone, total PSA, free PSA, PFP or weight-adjusted
IGF-1 (Table 2), or on systolic blood pressure (∆a = -1.65
± 2.78, ∆w = -3.05 ± 2.78 mmHg; P = 0.61) and diastolic
blood pressure (∆a = -2.50 ± 1.52 mmHg, ∆w = -3.45 ± 1.52
P = 0.54). However, a linear mixed model showed that,
although PSA did not change, the ratio of free PSA:total
PSA increased and approached significance (P = 0.07).
Urinary symptoms
The average score was 7.33 ± 5.83 following the usual diet
and 6.95 ± 5.66 following the walnut supplement diet.
The "total symptom score" was similar for both diets (P =
0.49).
Discussion
The present study showed that substituting 3 oz of wal-
nuts per day for fat sources in an Average American Diet
significantly increased intake of γ-T and mono- and poly-
unsaturated fats and resulted in a significant decrease in
serum α-T:γ-T, with a trend towards an increase in serum
γ-T and PFP, in this population of older men at risk for
prostate cancer. The ratio of serum α-T:γ-T, which
decreased almost four-fold, is of particular interest
because it specifically contrasts changes in the two forms
of vitamin E and also because it should be less affected by
confounding variables such as lipids [37]. These results
are consistent with a study by Lemcke-Norojarvi et al [38],
which reported that feeding oils containing differing
amounts of α- and γ-T resulted in an increase in serum γ-
T but not α-T, and a decrease in α-T:γ-T. A previous study
identified a higher ratio of serum α-T:γ-T as an important
difference between patients with heart disease and healthy
controls [39]. Thus, a lower ratio of serum α-T:γ-T may be
protective against heart disease, and walnuts may be ben-
eficial in lowering this ratio. Further research is needed to
explore the effects of mixed tocopherols on markers of
heart disease risk, such as platelet function. A recent study
conducted in subjects with type II diabetes showed that,
although supplementation with mixed tocopherols (500
mg/d total: 315 mg of γ-T, 75 mg of α-T and 110 mg δ-
tocopherol) increased both serum α-T and γ-T and eryth-
rocyte and platelet γ-T four-fold, it did not improve plate-
let activation and endothelial function [40]. The lack of an
increase in α-T and the trend for a decrease in γ-T in the
present study may be explained by the fact that we fed a
much lower "dose" of tocopherols as walnuts in different
proportions (i.e. 0.52 mg/d of α-T and 15.6 mg/d of γ-T)
than did Clarke et al [40].
Our timecourse experiment confirmed that tocopherol
absorption from walnuts, a whole food source of vitamin
E, is similar to that which has been reported following a
vitamin E supplement [27,41]. Our experiment also
showed a significant increase in the ratio of γ-T to triglyc-
erides. Although the average concentration of serum trig-
lycerides decreased between 4 and 8 h, serum γ-T
Table 1: Average intake from food records collected during feeding study – Average American vs. Intervention Diet1
Average American Diet Intervention Diet, intake with walnuts P2
Total energy, kcal/d 2041 ± 504 2519 ± 512 0.003
Total fat, g/d 81.1 ± 24.6 125 ± 21.2 < 0.0001
Saturated fat, g/d 29.7 ± 9.86 32.2 ± 9.04 0.28
Monounsaturated fat, g/d 30.4 ± 9.74 37.3 ± 7.79 0.02
Polyunsaturated fat, g/d 16.2 ± 10.1 45.2 ± 11.2 < 0.0001
Alpha-tocopherol, mg/d 9.32 ± 6.50 14.1 ± 8.01 0.63
Gamma-tocopherol, mg/d 15.0 ± 5.93 28.6 ± 7.81 < 0.0001
1Values are means ± SD, n = 20.
2P for comparison of Average American Diet and Intervention Diet With Walnuts.Nutrition Journal 2008, 7:13 http://www.nutritionj.com/content/7/1/13
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increased between 1 and 8 h (Figure 1), suggesting that
the two do not move in parallel. While the action of lipo-
protein lipase and the hepatic uptake of chylomicron rem-
nants causes serum triglyceride concentrations to drop,
transfer of γ-T to longer-lived lipoprotein particles may
cause serum γ-T to rise over a longer period and may
explain the significant increase seen in triglyceride – nor-
malized serum γ-T. Further work is needed to determine if
serum γ-T would have continued to rise beyond 8 h in our
experiment. Although 8 h is sufficient for measuring max-
imal postprandial changes in serum lipids, our data sug-
gest that a period of at least 8 h, and possibly longer, is
needed for a maximal increase in postprandial serum γ-T
from a whole food source, as has been demonstrated pre-
viously in vitamin E supplementation studies [42]. None-
theless, our timecourse experiment does show an increase
in serum γ-T over an 8 h time period indicating its bioa-
vailability in the walnut supplement study.
Previous research suggests that walnut consumption is not
associated with a higher body weight unless, as would be
expected, energy intake exceeds energy expenditure
[43,44]. In our study, mean weight decreased only during
the usual diet period (net difference in weight change was
-0.85 ± 0.37 kg between the two diets). Reported caloric
intake was significantly less on the usual diet than during
the walnut supplement diet, which likely explains the very
modest weight loss observed. During the walnut supple-
ment diet, even though subjects reported a higher energy
intake, they maintained their body weight. Further,
adjusting our results for weight as described above
showed the changes in tocopherols persisted even follow-
ing weight adjustment.
For several reasons, we suspect that the relative good
health of our participants (aside from their prostate symp-
toms) may have contributed to the lack of significant
treatment effects for many of our serum hormone and
lipid variables. Our participants learned about the study
through a newspaper advertisement targeting men con-
cerned about elevated PSA levels and interested in using a
dietary intervention to possibly improve prostate health.
Consequently, they were "self-selected" and might have
been more health-conscious, and thus healthier, than
males of the same age in the general population. Although
they had elevated PSA levels, their IGF-1 and total choles-
terol levels were lower and their HDL cholesterol was
higher than observed in other studies [7,45], indicating
that they might have been healthier than their peers.
First, the men in our study were in the lowest quartile of
serum IGF-1 when compared to individuals in the Physi-
Table 2: Mean change from baseline in serum biomarkers during feeding study – Average American vs. Intervention Diet1
Baseline Change Following Average 
American Diet2
Change Following Intervention 
Diet2
P-value for Difference in 
Change
Total cholesterol, mmol/L 5.01 ± 0.16 -0.02 ± 0.12 -0.18 ± 0.12 0.13
HDL, mmol/L 1.36 ± 0.06 -0.04 ± 0.04 -0.05 ± 0.04 0.95
Oxidized LDL, mmol/L 2.61 ± 0.16 -0.15 ± 0.11 -0.16 ± 0.11 0.98
Triglycerides3, mmol/L 1.31 ± 1.01 1.00 ± 1.00 1.00 ± 1.00 0.48
LDL, mmol/L 3.11 ± 0.15 0.03 ± 0.13 -0.10 ± 0.13 0.21
LDL:HDL 2.37 ± 0.16 0.15 ± 0.15 0.04 ± 0.15 0.34
Non-HDL:HDL 2.79 ± 0.19 0.18 ± 0.15 0.03 ± 0.15 0.28
Total PSA, µg/L 5.02 ± 0.63 -0.07 ± 0.35 0.05 ± 0.36 0.75
Free PSA, µg/L 0.92 ± 0.13 0.05 ± 0.10 0.13 ± 0.10 0.56
Percent Free PSA3, % 38.8 ± 1.04 1.03 ± 1.03 0.99 ± 1.03 0.07
Testosterone nmol/L 16.4 ± 1.11 -0.60 ± 0.70 -0.75 ± 0.70 0.82
Bioavailable testosterone nmol/L 4.66 ± 0.29 -0.35 ± 0.26 -0.34 ± 0.26 0.99
Percent bioavailable 
testosterone, %
0.92 ± 0.13 -0.85 ± 0.93 -0.45 ± 0.94 0.66
IGF-1, µg/L 143 ± 9.11 10.6 ± 5.85 1.79 ± 6.07 0.13
3α-Androstanediol glucuronide, 
nmol/L
13.8 ± 1.55 -0.02 ± 0.01 -0.02 ± 0.01 0.90
Estradiol, pmol/L 97.7 ± 5.74 1.22 ± 4.02 -3.85 ± 4.02 0.34
Alpha-tocopherol,4 µmol/L 29.3 ± 2.19 -0.71 ± 1.30 -2.65 ± 1.30 0.13
Gamma- tocopherol,4 µmol/L 4.14 ± 0.43 0.26 ± 0.52 0.83 ± 0.52 0.08
Tocopherol ratio alpha:gamma4 11.0 ± 9.91 -0.51 ± 1.99 -3.49 ± 1.99 0.01
1Values are least-squares means ± SEM, n = 21. Data presented from the final model, in which weight was significant only for tocopherols and IGF-
1 and was omitted for all other variables.
2Change scores calculated for each diet as ∆ = mean concentration following diet – mean concentration at baseline.
3Triglyceride and percent free PSA (n = 20) change score data were log-transformed, and change scores are presented as geometric means.
4 n = 20. Tocopherol change score adjusted for change in weight between the two diets.Nutrition Journal 2008, 7:13 http://www.nutritionj.com/content/7/1/13
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cian's Health Study, another study with participants who
were more likely to be health-conscious [7]. However, the
effect size was small to moderate (0.43) for our serum
IGF-1 data, indicating that a significant decrease in IGF-1
might have been detected if the sample size had been
larger.
Second, among our participants, mean serum total choles-
terol was lower (5.00 mmol/L, usual diet and 4.82 mmol/
L, walnut supplement diet) and mean serum HDL choles-
terol was higher (approximately 1.32 mmol/L, both diets)
when compared to cholesterol levels of men in a large
heart-health study (5.33 mmol/L, total cholesterol and
1.11 mmol/L, HDL cholesterol) [45]. Many of the previ-
ous feeding studies with walnuts that have reported favo-
rable improvements in serum lipids have studied subjects
with hypercholesterolemia [24,26,46]. Further, whereas
these previous studies employed a controlled feeding
design, in which participants followed a prescribed, low-
fat diet, the present study employed a free-living design, in
which participants followed their typical diet with or
without walnuts, depending on the diet period. By nature
of the design, a free-living feeding study cannot minimize
dietary variation as well as a controlled feeding study, and
this can make producing significant dietary change more
difficult, especially given the small sample studied.
Previous research on the role of dietary γ-T in prostate can-
cer and CVD is limited [47]. To our knowledge, this is one
of the first studies to assess the effects of walnut intake on
markers of prostate health, to demonstrate the bioavaila-
bility of γ-T following walnut consumption and to con-
trast the postprandial timecourse of dietary lipids and
tocopherols. Although the tocopherol ratio significantly
improved with walnut consumption, the primary markers
of prostate health (PSA and urinary symptoms) were not
changed significantly by this 8-week dietary intervention.
However, there was a nonsignificant increase in PFP (the
ratio of free PSA: total PSA) during both diets, and
research has indicated that the use of PFP in combination
with total PSA may improve specificity of diagnosis and
decrease false-positives [5]. Future work is needed to
determine whether dietary tocopherols must be adminis-
tered over longer periods of time to have a meaningful
effect on prostate health and if they are effective both as a
preventative measure against the development of prostate
disease and as a secondary prevention strategy.
Nevertheless, the significant decrease in α-T: γ-T (without
changes in body weight) in response to incorporation of
75 g of walnut/d in the diet offers the promise of signifi-
cant benefits for both vascular and prostate health.
Our results are also important in light of recent research
on the relationship between α-linolenic acid and prostate
cancer, since walnuts are a rich source of α-linolenic acid
(6.81 g/75 g walnuts) [19]. A meta-analysis of nine obser-
vational studies (four prospective studies and five non-
prospective studies) assessed the relationship between
prostate cancer incidence or prevalence and intake or
blood levels of α-linolenic acid [48]. This meta-analysis
reported that α-linolenic acid increased risk of prostate
cancer (1.70; 95% CI 1.12–2.58). For the prospective
studies, however, the combined estimate of relative risk
for prostate cancer incidence was 1.32 (95% CI 0.80–
2.18). More recent evidence reports no association
between α-linolenic acid intake and risk of prostate cancer
[49,50] (also, Simon JA, Tanzman JS, Sabaté J: Lack of
effect of walnuts on serum levels of prostate specific anti-
gen: a brief report, submitted). The Lyon Diet Heart Study,
a randomized secondary prevention trial, found that sub-
jects consuming a Mediterranean diet with 0.8% of calo-
ries from α-linolenic acid were not at increased risk of
prostate cancer compared to those consuming a diet that
met the criteria of an American Heart Association Step I
Diet [49]. The prospective study conducted by Koralek et
al [50] with 29,592 participants (mostly Caucasian) of the
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer
Screening Trial reported no association between dietary
intake of total α-linolenic acid (multivariate relative risk
for highest vs. lowest quintile of intake/d [1.75 g/d vs.
1.38 g/d] was 0.94, 95% CI = 0.81–1.09) and α-linolenic
acid from specific food sources and risk of total prostate
cancer or prostate tumors that were defined by stage and
grade. Consistent with our study results, Simon et al
(Simon JA, Tanzman JS, Sabaté J: Lack of effect of walnuts
on serum levels of prostate specific antigen: a brief report,
submitted) reported that short term consumption of wal-
nuts did not affect PSA levels adversely in healthy men.
Conclusion
Our data offer no support that walnuts, which are high in
α-linolenic acid, increase prostate cancer risk, as measured
by serum PSA, androgen hormones and urinary symp-
toms, the primary markers of prostate health. In contrast,
our results suggest that walnuts may be beneficial and
improve serum γ-T and α-T: γ-T, two biomarkers that are
important in prostate and vascular health. However, addi-
tional research is needed to assess the long-term efficacy
of walnut consumption on PSA and other primary meas-
ures of prostate health.
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